|
|
|
Welcome to the Quality Counts. For those health conscious consumers and medical professionals that are looking to purchase nutritional supplements, vitamins, herbs, learning about medications, losing weight, health food, low carbs, high protein nutrition, and exercise, you have come to the right place. Quality Counts serves both the medical practitioner and consumer interested in nutritional therapy and alternative medicine.
Home > Health Conditions > Hypertension >
Alpha Blockers
Alpha Blockers
Related Topics:
News & Research:
-
Finasteride May Be Helpful for Benign Prostatic Hypertrophy - Medscape,
10/8/10 - "Finasteride improves long-term urinary
symptoms versus placebo, but is less effective than doxazosin," the study
authors write. "Long-term combination therapy with alpha blockers
(doxazosin, terazosin) improves symptoms significantly better than
finasteride monotherapy. Finasteride + doxazosin improves symptoms equally —
and clinically — to doxazosin alone. In comparison to doxazosin, finasteride
+ doxazosin appears to improve urinary symptoms only in men with medium (25
to < 40 mL) or large prostates (≥ 40 mL), but not in men with small
prostates (25 mL)."
- FDA
Approves Dutasteride/Tamsulosin Combo Pill for BPH - Medscape, 6/18/10 -
"daily use of the drug combination yielded significantly
greater relief of BPH symptoms compared with either 0.5 mg dutasteride or 0.4 mg
tamsulosin alone, as measured by point changes on the International Prostate
Symptom scale from baseline (mean Δ, −6.2 vs −4.9 and −4.3; P < .001 for both).
The difference was observed by month 9 and continued through month 24" - See
dutasteride at
OffshoreRX.com.
-
Alfuzosin Improves Ejaculatory Dysfunction in Men With Probable BPH -
Medscape, 4/20/10 - "Alfuzosin (Uroxatral, Sanofi
Aventis), a uroselective alpha-1-adrenergic receptor blocker, ameliorates
ejaculatory dysfunction in sexually active men with lower urinary tract
symptoms (LUTS) suggestive of benign prostatic hypertrophy (BPH) ...
Alfuzosin significantly improved IPSS score (7.9 [–41%]; P < .0001) and
nocturia (–0.9 [–18%]; P < .001) from baseline. Bother due to LUTS also
significantly improved (–1.5 [–28%]; P < .0001)"
-
Generic Drug for Enlarged Prostate Approved - WebMD, 3/2/10 -
"The first generic version of Flomax, a medication
to treat the signs and symptoms of an enlarged prostate gland, has won the
approval of the FDA"
-
Combination therapy more effective for enlarged prostate - Science Daily,
3/2/10 - "On the strengths of both dutasteride and tamsulosin, participants
reported fewer symptoms, and we observed a 25 percent reduction in prostate
volume ... subjects who received the combination therapy also showed a 50
percent reduction of prostate-specific antigen (PSA), a protein produced by both
cancerous and noncancerous prostate tissue ... Compared with tamsulosin alone,
the combination of drugs reduced the incidence of acute urinary retention by 67
percent and reduced the need for BPH-related surgery by 70 percent" - See - See
dutasteride at OffshoreRx.com.
-
Use of alpha-Blockers for Hypertension Declined After Publication of Unfavorable Clinical Trial Results - Doctor's Guide, 1/6/04
Abstracts:
-
A randomized
crossover study comparing patient preference for tamsulosin and silodosin in
patients with lower urinary tract symptoms associated with benign prostatic
hyperplasia - J Int Med Res. 2011;39(1):129-42 - "A significant difference
was observed between the proportion of patients who preferred tamsulosin (59/84
patients; 70.2%) and those who preferred silodosin (18/84 patients; 21.4%). A
major reason for preference of either drug was 'good efficacy'. Incidence of
adverse effects was significantly lower with tamsulosin (3/91 patients; 3.3%)
than with silodosin (25/88 patients; 28.4%). These findings indicate that
tamsulosin is very effective for BPH, has few adverse effects and that patients
want to continue to use it" - See tamsulosin (generic Flomax) at OffshoreRX.com.
-
The effects of combination therapy with dutasteride plus tamsulosin on clinical
outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men
in the CombAT study - Prostate Cancer Prostatic Dis. 2011 Apr 19 -
"Patients were randomised to daily tamsulosin 0.4 mg,
dutasteride 0.5 mg or both for 4 years ... Combination therapy significantly
reduced the relative risk of AUR or BPH-related surgery compared with either
monotherapy at 4 years, and also significantly reduced the risk of BPH clinical
progression. Combination therapy also provided significantly greater symptom
improvement than either monotherapy at 4 years. Safety and tolerability of
dutasteride plus tamsulosin was consistent with previous experience of this
combination and with the monotherapies. These data provide further evidence to
support the use of long-term combination therapy (dutasteride plus tamsulosin)
in men with moderate-to-severe lower urinary tract symptoms because of BPH and
prostatic enlargement"
-
Comparison
of Effects of Alpha Receptor Blockers on Endothelial Functions and Coagulation
Parameters in Patients with Benign Prostatic Hyperplasia - Urology. 2011 Jan
20 - "When coagulation tests were evaluated, there were
significant increases in bleeding and coagulation times in the groups using
doxazosin and terazosin. Doxazosin and terazosin lowered arterial blood pressure
significantly compared with other treatments. With regard to effects on
endothelial function, there were significant differences in flow-mediated
dilation rates of the brachial artery at 60 and 90 seconds before and during
treatment in the alfuzosin and terazosin groups ... Alpha receptor blockers can
decrease the risk of cardiovascular complications by both reducing platelet
aggregation and protecting endothelial functions in patients with prostatic
hyperplasia. The only drug with a favorable effect in all 4 areas of interest,
including BPH symptoms, blood pressure, platelet aggregation, and endothelial
functions, was terazosin"
-
Reduction of
Prostate-specific Antigen After Tamsulosin Treatment in Patients With Elevated
Prostate-specific Antigen and Lower Urinary Tract Symptoms Associated With Low
Incidence of Prostate Cancer at Biopsy - Urology. 2010 Jun 8 -
"A total of 80 patients completed the present study. The
mean patient age was 66.3 years, and the mean PSA level was 7.8 +/- 8.4 ng/mL at
baseline and 7.1 +/- 9.1 ng/mL after treatment (P < .001). A total of 29
patients (36.25%) were diagnosed with prostate cancer from the biopsy findings.
A significant increment in the PSA level was observed in patients with prostate
cancer (6.7 versus 7.9 ng/mL; P = .002). A significant decrease in the PSA level
was observed in patients with negative biopsy findings (6.9 versus 5.1 ng/mL, P
= .000). Of the 38 patients with a decrease in the PSA level, 1 (2.6%) was
diagnosed with prostate cancer and 37 (97.4%) with an benign prostatic
hyperplasia/prostatitis. Of the 42 patients with no change in the PSA level, 28
(66.7%) had prostate cancer and 14 (33.3%) had negative findings. A change in
PSA level after treatment gave a sensitivity of 96.6%, specificity of 72.5%, and
diagnostic accuracy of 81% for prostate cancer. CONCLUSIONS: Treatment with
tamsulosin seemed to reduce the PSA levels and identified patients at high risk
of prostate cancer"
-
Effect of
dutasteride, tamsulosin and the combination on patient-reported quality of life
and treatment satisfaction in men with moderate-to-severe benign prostatic
hyperplasia: 4-year data from the CombAT study - Int J Clin Pract. 2010 May
7 - "Subjects were randomised to receive 0.5 mg dutasteride, 0.4 mg tamsulosin
or the combination once daily for 4 years ... At 4 years, combination therapy
resulted in significantly superior improvements from baseline in BII and IPSS Q8
than either monotherapy; these benefits were observed from 3 months onwards
compared with dutasteride and from 9 months (BII) or 12 months (IPSS Q8) onwards
compared with tamsulosin. Also at 4 years, the PPSM questionnaire showed that a
significantly higher proportion of patients was satisfied with, and would
request treatment with, combination therapy compared with either monotherapy.
Conclusions: Combination therapy (dutasteride plus tamsulosin) provides
significantly superior improvements in patient-reported quality of life and
treatment satisfaction than either monotherapy at 4 years in men with
moderate-to-severe BPH symptoms" - See dutasteride at
OffshoreRX.com.
-
alpha-Blocker Use Is Associated With Decreased Risk of Sexual Dysfunction
- Urology. 2009 May 8 - "Lower urinary tract
symptoms (LUTS) ... alpha-Blocker use was associated with a decreased risk
of sexual dysfunction across all domains for men >/=50 years old
(age-adjusted hazard ratio 0.53-0.69). A decreased risk of erectile
dysfunction and low libido remained significant only among those using
alpha-blockers who also experienced an improvement in LUTS (P = .01)"
-
Safety
and efficacy of the simultaneous administration of udenafil and an
alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS
- Int J Impot Res. 2009 Feb 5 - "The
coadministration of udenafil and an alpha-blocker in patients with comorbid
BPH and ED was safe and gave significant improvements in both LUTS and ED"
- Note: Udenafil isn't available in the U.S. but it would seem that
the results would be the same with the competition.
-
Association of Sexual Dysfunction With Lower Urinary Tract Symptoms of BPH
and BPH Medical Therapies: Results From the BPH Registry - Urology. 2009
Jan 21 - "The severity of lower urinary tract
symptoms (LUTS) has correlated with erectile dysfunction (ED) and
ejaculatory dysfunction (EjD) ... The alpha(1A)-subtype nonsuperselective
quinazoline alpha(1)-blockers alfuzosin, doxazosin, and terazosin appeared
to be associated with better ejaculatory function than were the
alpha(1A)-subtype superselective sulfonamide alpha(1)-blocker tamsulosin,
5alpha-reductase inhibitors, and alpha(1)-blocker plus 5alpha-reductase
inhibitor combination therapy"
-
Sexuality and the management of BPH with alfuzosin (SAMBA) trial - Int J
Impot Res. 2008 Dec 11 - "Alfuzosin for the
treatment of patients with BPH is effective in improving sexual function, as
well as lower urinary tract symptoms (LUTSs) and quality of life, and is
well tolerated"
Related Searches:
70603
|
